Population modelling to describe pharmacokinetics of amiodarone in rats: Relevance of plasma protein and tissue depot binding

European Journal of Pharmaceutical Sciences

Volumn 30, Issue 2, 2007, Pages 190-197

  Campos Moreno, Eduardo ^a   Merino Sanjuán, Matilde ^a   Merino, Virginia ^a   Nácher, Amparo ^a   Martín Algarra, Rafael V ^b   Casabó, Vicente G ^a  

^a UNIVERSITY OF VALENCIA   (Spain)

^b UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

Author keywords

Amiodarone; Non linear mixed effects; Pharmacokinetic models; Plasma protein binding; Tissular depot

Indexed keywords

AMIODARONE; PLASMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG DISPOSITION; DRUG MEGADOSE; MALE; NONHUMAN; NONLINEAR SYSTEM; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RAT;

AMIODARONE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; AREA UNDER CURVE; BLOOD PROTEINS; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; RATS; RATS, WISTAR; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 33846448545     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2006.11.006     Document Type: Article

References (26)

1. Bardy G.H., Lee K.L., Mark D.B., Poole J.E., Packer D.L., Boineau R., Domanski M., Troutman C., Anderson J., Johnson G., McNulty S.E., Clapp-Channing N., Davidson-Ray L.D., Fraulo E.S., Fishbein D.P., Luceri R.M., Ip J.H., and and Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) Investigators. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352 (2005) 225-237
2. Beal S.L., and Sheiner L.B. NONMEM User's Guides (1992), NONMEM Project Group, University of California, San Francisco
3. Campbell T.J., and Williams K.M. Therapeutic drug monitoring: antiarrhythmic drugs. Br. J. Clin. Pharmacol. 52 Suppl. 1 (2001) 21S-34S
4. Funakoshi S., Murakami T., Yumoto R., Kiribayashi Y., and Takano M. Role of organic anion transporting polypeptide 2 in pharmacokinetics of digoxin and beta-methyldigoxin in rats. J. Pharm. Sci. 94 6 (2005) 1196-1203
5. Karlsson M., and Sheiner L. Estimation of bioavailability when clearance varies with time. Clin. Pharmacol. Ther. 55 (1994) 623-637
6. Karnes H.T., and March C. Precision, accuracy, and data acceptance criteria in biopharmaceutical analysis. Pharm. Res. 10 (1993) 1420-1426
7. Kashima A., Funahashi M., Fukumoto K., Komamura K., Kamakura S., Kitakaze M., and Ueno K. Pharmacokinetic characteristics of amiodarone in long-term oral therapy in Japanese population. Biol. Pharm. Bull. 28 10 (2005) 1934-1938
8. Kerstein J., Soodan A., Qamar M., Majid M., Lichstein E., Hollander G., and Shani J. Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. Chest 126 (2004) 716-724
9. Klein H., Auricchio A., Reek S., and Geller C. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. Am. J. Cardiol. 83 (1999) 91D-97D
10. Lalloz M.R., Byfield P.G., Greenwood R.M., and Himsworth R.L. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands. J. Pharm. Pharmacol. 36 6 (1984) 366-372
11. Latini R., Tognoni G., and Kates R.E. Clinical pharmacokinetics of amiodarone. Clin. Pharmacokinet. 9 (1984) 136-156
12. Lucchesi B.R. Antiarrhythmic drugs. In: Antoaccio M.J. (Ed). Cardiovascular Pharmacology. 3rd ed. (1990), Raven, New York 369-483
13. Martín Algarra R.V., Pascual Costa R.M., Merino M., and Casabó V.G. Effects of surfactants on amiodarone intestinal absorption. I. Sodium laurylsulfate. Pharm. Res. 11 (1994) 1042-1047
14. Mason J.W. Amiodarone. N. Engl. J. Med. 316 (1987) 455-466
15. Mc Evoy G.K. Amiodarone Hydrochloride in AHFS Drug Information (2003), American Society of Health System Pharmacists Inc., Bethesda pp. 1545-1558
16. Metzler C.M. PCNONLIN Version 3.0. Software for the Statistical Analysis of Nonlinear Models on Micros (1989), SCI Software
17. Muñoz M.J., Merino Sanjuán M., Lledó García R., Casabó V.G., Máñez Castillejo F.J., and Nácher A. Use of nonlinear mixed effect modelling for the intestinal absorption data: application to ritonavir in the rat. Eur. J. Pharm. Biopharm. 61 (2005) 20-26
18. Naccarelli G.V., Wolbrette D.L., Dell'Orfano J.T., Patel H.M., and Luck J.C. Amiodarone: what have we learned from clinical trials?. Clin. Cardiol. 23 (2000) 73-82
19. Naccarelli G.V., Wolbrette D.L., Patel H.M., and Luck J.C. Amiodarone: clinical trials. Curr. Opin. Cardiol. 15 (2000) 64-72
20. Nattel S., and Talajic M. Recent advances in understanding the pharmacology of amiodarone. Drugs 36 (1988) 121-131
21. Ohyama K., Nakajima M., Nakamura S., Shimada N., Yamazaki H., and Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab. Dispos. 28 11 (2000) 1303-1310
22. Pollak P.T., Bouillon T., and Shafer S.L. Population pharmacokinetics of long-term oral amiodarone therapy. Clin. Pharmacol. Ther. 67 (2000) 642-652
23. Pollak P.T., and Shafer S.L. Use of population modeling to define rational monitoring of amiodarone hepatic effects. Clin. Pharmacol. Ther. 75 4 (2004) 342-351
24. Ruiz Carretero P., Merino Sanjuán M., Nácher A., and Casabó V.G. Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. Eur. J. Pharm. Sci. 21 (2004) 217-223
25. Shayeganpour A., Jun A.S., and Brocks D.R. Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm. Drug Dispos. 26 6 (2005) 249-257
26. Vadiei K., Troy S., Korth-Bradley J., Chiang S.T., and Zimmerman J.J. Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. J. Clin. Pharmacol. 37 (1997) 610-617